The Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
The goal of this study was to assess the efficacy and safety of FDC therapy with triple
therapy of Telmisartan 40 mg/Amlodipine 5 mg/Rosuvastatin 10mg in Korean patients with both
hypertension and dyslipidemia.
Phase:
Phase 4
Details
Lead Sponsor:
Hyo-Soo Kim
Treatments:
Amlodipine Amlodipine, atorvastatin drug combination Rosuvastatin Calcium Telmisartan